Product
Supplier
Encyclopedia
Inquiry
Home > Active Pharmaceutical Ingredients > Inhibitor Drugs > Retatrutide for Sale > Premium Refined Peptide Substance for Lab R&D Formulation
Premium Refined Peptide Substance for Lab R&D Formulation buy - large image1
Premium Refined Peptide Substance for Lab R&D Formulation buy - image1
Premium Refined Peptide Substance for Lab R&D Formulation buy - image2
Premium Refined Peptide Substance for Lab R&D Formulation buy - image3
Premium Refined Peptide Substance for Lab R&D Formulation buy - image4
Premium Refined Peptide Substance for Lab R&D Formulation buy - image5
Premium Refined Peptide Substance for Lab R&D Formulation buy - image6

Premium Refined Peptide Substance for Lab R&D Formulation

COA 7024 Inquiries

Unit Price: Get Latest Price
CAS No.:

2381089-83-2

Grade:

Chemically Pure

Content:

99%

Port:

ZHOUSHAN

Packaging:

10mg*10vials

Price valid (until):

2026-09-11

Company Type:
Trader
Location:
China
Payment Terms:
TT against copy of documents,D/A,100% TT in advance
Average Lead Time:
15 days
Qualification:
Main Products:

Retatrutide,Tirzepatide,Semaglutide,GHK-CU

  • Product Description

  • Seller Information

  • History Price

  • Inquiry History

  • Description


      Product Detail  


    This premium synthetic dual-target peptide raw material is developed for metabolic mechanism research and laboratory formulation development. Consisting of 39 amino acids with a C20 fatty diacid side chain, the molecular structure enables albumin binding and prolongs the action cycle, making it highly sought-after among research institutions and formulation developers focusing on metabolic studies. Our peptide adopts mature solid-phase synthesis combined with multi-stage purification technology, supplied in the form of lyophilized white powder with low related-substance content and stable physicochemical properties.

    Each batch is tested by HPLC and other analytical testing methods. Complete COA documents can be provided to verify purity, moisture, residual solvent and impurity indicators, ensuring repeatable experimental results for your research projects. Comprehensive quality control runs through the whole manufacturing workflow, including synthesis, purification, freeze-drying and finished packaging. Goods are packed in moisture-proof and light-proof sealed containers to prevent degradation during long-distance international logistics and long-term storage.

    We focus on bulk wholesale cooperation with global distributors, laboratories and formula developers. The standard production lead time is around 15 days after deposit confirmation. Multiple payment channels are supported, including BTC, USDT, Wise transfer and international bank transfer to satisfy transaction demands from different regions.

    As a reliable peptide manufacturer, we guarantee sustainable supply capacity and timely communication. Competitive preferential prices are available for large-volume orders. Please note that this product is strictly limited to laboratory scientific research purposes and is not intended for direct human administration. If you need detailed packing specifications and official quotations, kindly inform us of your expected purchasing quantity.

    Items Specifications
    vial mg
    tude g
    bag kg
    ECHEMI Editorial Reference
    Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide inhibits human GCGR, GIPR and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively and mouse GCGR, GIPR, and GLP-1R with EC50 values of 2.32, 0.191 and 0.794 nM, respectively. It is an important tool for obesity research.Retatrutide potently activates the GLP-1R signaling pathway to stimulate glucose-dependent insulin secretion through activity at the GIP receptor (GIPR) or the GLP-1R.Retatrutide is a synthetic peptide with glucose-lowering effects. It is an antidiabetic agent against type 2 diabetes (T2D), stimulating insulin and suppressing glucagon secretion in a glucose-dependent manner.Retatrutide was also shown to delay gastric emptying, lower fasting and postprandial glucose concentration, decrease food intake and reduce body weight in patients with type 2 diabetes.
    Retatrutide (LY-3437943) was discovered by the American pharmaceutical company Eli Lilly and Company. It is a triple glucagon hormone receptor agonist (GLP-1, GIP, and GCGR receptors) for obesity. The 2024 Lasker~DeBakey Clinical Medical Research Award has been given to Joel Habener and Svetlana Mojsov for their discovery of a new hormone GLP-1(7-37) and to Lotte Knudsen for her role in developing sustained acting versions of this hormone as a treatment for obesity.

    Certificates

    Basic Info
    Product Name:

    Retatrutide

    Other Name:

    Retatrutide;GIPR/GLP-1R;LY3437943Retatrutide;Retalutide;Retatrutide (sodium salt);Retatrutide RT5;retatrutide 5mg;Retatratide

    CAS No.:

    2381089-83-2

    InChIKeys:

    MLOLQJNKXBNWFW-SAGGEDDASA-N

    Molecular Weight:

    0

    EC Number:

    200-001-8

    Color/Form:

    White lyophilized

    Categories:

    Inhibitor Drugs

    Characteristics
    Water Solubility:

    Soluble in water (5mg/ml).

    Storage Conditions:

    -20°C

    Critical Temperature & Pressure:

    -20°C

    Research
    Class:

    Triple agonist — GCGR, GIPR, GLP-1R

    Status:

    Investigational (Phase 3)

    Mechanism:

    Simultaneously activates glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Engineered from the native GIP backbone with amino acid substitutions to confer GCGR and GLP-1R activity.

    EC50 (Human GCGR):

    5.79 nM

    EC50 (Mouse GIPR):

    0.191 nM

    EC50 (Mouse GLP1R):

    0.794 nM

    EC50 (Mouse GCGR):

    2.32 nM

    EC50 (Human GLP1R):

    0.775 nM

    EC50 (Human GIPR):

    0.0643 nM

    Source:

    Jastreboff AM, et al. N Engl J Med. 2023;389(6):514-526.DOI

    Clinical Development:

    NCT04881760; NCT05882045; NCT06354660

    References
    ChEMBL:

    CHEMBL5095485

    DrugBank:

    DB18993

    KEGG DRUG:

    D12430

    PubChem:

    PubChem

    Disclaimer:

    Retatrutide is an investigational compound not yet approved by FDA or EMA. This listing is for industrial and laboratory research use only. Product information on ECHEMI is provided for sourcing and specification reference. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.

  • Seller Information
    Business Type:

    Trader

    Main Products:

    Retatrutide,Tirzepatide,Semaglutide,GHK-CU

    Location:

    Room 1209, 12th Floor, Unit 1, Building 1, Block A, Shenglong Plaza, No.80 Weiyang Road, Weiyang District, Xi'an City, Shaanxi Province, P.R.China

    Payment Terms:

    TT against copy of documents,D/A,100% TT in advance

    Average lead Time:

    15 days

    Total Annual Revenue:

    $1 million-$2.5 million

    Total Employees:

    11-50

    Year of Establishment:

    2025

    Xi'an Haoming Technology Co., Ltd. Founded in 2020, we are a professional supplier of high‑quality functional peptides. Our main product range includes weight‑loss peptides, anti‑wrinkle peptides, tanning peptides and other active peptide ingredients, widely used in cosmetics, skincare and health‑care industries. Strict quality‑control standards are applied throughout raw‑material screening, production and shipment to deliver consistent and reliable product quality.

    Putting customer value first, we supply premium‑grade products with competitive pricing, flexible MOQs and on‑time delivery. Our goods are well‑sold across Europe, the UK, the USA, Canada, Australia and other regions, earning wide recognition and trust from global buyers.

    We maintain stable independent international logistics channels covering the USA, Canada, UK, Germany, Spain, Poland, the Netherlands, Russia, Kazakhstan and more. One‑stop door‑to‑door delivery with full customs‑clearance service is available to free customers from cross‑border logistics troubles.

    Upholding the business philosophy of “Survive by Quality, Develop by Reputation”, Xi'an Haoming Technology Co., Ltd. keeps tight control over raw‑material procurement and production procedures. Free samples are offered prior to formal orders. All items are manufactured efficiently under high‑safety standards. Backed by a complete after‑sales system, we deliver prompt replies and professional solutions for satisfying cooperation.

    With consistent integrity, professional technical support and efficient service, we keep providing overseas partners with stable quality, competitive rates and reliable after‑sales support. Xi'an Haoming Technology Co., Ltd. aims to be your trusted long‑term supplier for peptide raw materials.

  • Weekly Price

    The chart shows the price trend of the product in the past 12 months.

  • Inquiry History
    7024 Inquiries
    Country Product Purchase Quantity Date Posted
    United States

    Retatrutide 2381089-83-2

    3 MT Mar 28, 2026
    United Kingdom

    Retatrutide - 2381089-83-2

    1 G Feb 10, 2026
    United States

    Retatrutide CAS 2381089-83-2 10mg vial

    20 MT Mar 7, 2026
    United States

    Factory Retatrutide API 99% Purity CAS 2381089-83-2

    5 KG Nov 10, 2025
    United Kingdom

    Peptide powder Retatrutide 99% pure for Body building cas 2381089-83-2 Weight Loss Peptide with COA

    1 MT Mar 22, 2026
    United States

    2381089-83-2

    100 G Jul 14, 2026
    United States

    2381089-83-2

    100 G Feb 24, 2026
    United States

    2381089-83-2

    100 MT Dec 9, 2023
    United States

    Retatrutide 2381089-83-2

    200 MG May 16, 2026
    United Kingdom

    2381089-83-2 retatrutide

    300 MG Feb 13, 2026
    United States

    Retatrutide 2381089-83-2 wholesale

    500 MT Nov 3, 2023
    United States

    Retatrutide CAS 2381089-83-2 99%

    10 PCS Feb 21, 2026
    Poland

    CAS 2381089-83-2 (Custom Peptide)

    40 MT Apr 10, 2026
    Austria

    Peptide Retatruide CAS 2381089-83-2

    100 MT Apr 4, 2026
    Austria

    Retatrutide CAS 2381089-83-2 10mg vial

    20 PCS Feb 10, 2026
    United States

    GLP-1 / GIP Retatrutide cas 2381089-83-2

    1 MT Oct 16, 2024
    United States

    Retatrutide 99% High Quality CAS 2381089-83-2

    1 G Jan 23, 2026
    United States

    Injection Peptide Tirzepatide/Retatrutide/ Semaglutide Peptides CAS 2381089-83-2

    10  Oct 21, 2023
    Australia

    GMP Grade 99% Retatrutide Lyophilized Powder CAS 2381089-83-2

    10 G Jun 12, 2026
    Palestine

    Factory 99% Purity Retatrutide Peptide CAS 2381089-83-2 Door-To-Door Service

    10 MG Mar 16, 2026
    Post an enquiry for this product

More from this Seller

pic ×

Scan the QR Code to Share

All products displayed on this website are only for non-medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.

According to relevant laws and regulations and the regulations of this website, units or individuals who purchase hazardous materials should obtain valid qualifications and qualification conditions.

The information shown above is provided by the enterprise itself, and the authenticity, accuracy and legitimacy of the content are the responsibility of the publishing company. ECHEMI does not bear any guarantee responsibility for this. Please be aware that risks in internet transactions objectively exist.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.